Literature DB >> 27635734

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke, S Thanendrarajan, J Sawyer, D Alapat, E Tian, C Stein, R Khan, C J Heuck, N Petty, D Avery, D Steward, R Smith, C Bailey, J Epstein, S Yaccoby, A Hoering, J Crowley, G Morgan, B Barlogie, F van Rhee.   

Abstract

Entities:  

Year:  2016        PMID： 27635734      PMCID： PMC5056975          DOI： 10.1038/bcj.2016.85

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
Correction to: Blood Cancer Journal (2016) 6, e453; doi:10.1038/bcj.2016.64 The purpose of this corrigendum is to publish grant support omitted in the manuscript 16-BCJ-0175T entitled, ‘Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling defined high-risk multiple myeloma'. Research related to Total Therapy 5 was supported by the P01 Grant awarded to the Myeloma Institute by the National Institutes of Health (P01CA055819).
  5 in total

1.  The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.

Authors:  Carolina Schinke; Antje Hoering; Hongwei Wang; Victoria Carlton; Sharmilan Thanandrarajan; Shayu Deshpande; Purvi Patel; Gabor Molnar; Sandra Susanibar; Meera Mohan; Pankaj Mathur; Muthukumar Radhakrishnan; Shadiqul Hoque; Jorge Jo Kamimoto; Monica Grazziutti; Frits van Rhee; Maurizio Zangari; Giovanni Insuasti-Beltran; Daisy Alapat; Ginell Post; Shmuel Yaccoby; Joshua Epstein; Leo Rasche; Sarah Johnson; Martin Moorhead; Tom Willis; Bart Barlogie; Brian Walker; Niels Weinhold; Faith E Davies; Gareth J Morgan
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

2.  PHF19 inhibition as a therapeutic target in multiple myeloma.

Authors:  Carolina D Schinke; Jordan T Bird; Pingping Qu; Shmuel Yaccoby; Valeriy V Lyzogubov; Randal Shelton; Wen Ling; Eileen M Boyle; Sharyu Deshpande; Stephanie D Byrum; Charity Washam; Samuel Mackintosh; Owen Stephens; Sharmilan Thanendrarajan; Maurizio Zangari; John Shaughnessy; Fenghuang Zhan; Bart Barlogie; Frits van Rhee; Brian A Walker
Journal:  Curr Res Transl Med       Date:  2021-04-22       Impact factor: 4.192

3.  Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.

Authors:  Carolina Schinke; Eileen M Boyle; Cody Ashby; Yan Wang; Valeriy Lyzogubov; Christopher Wardell; Pingping Qu; Antje Hoering; Shayu Deshpande; Katie Ryan; Sharmilan Thanendrarajan; Meera Mohan; Naveen Yarlagadda; Maliha Khan; Samrat Roy Choudhury; Maurizio Zangari; Frits van Rhee; Faith Davies; Bart Barlogie; Gareth Morgan; Brian A Walker
Journal:  Blood Cancer J       Date:  2020-06-19       Impact factor: 11.037

4.  Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.

Authors:  Dirk Hose; Susanne Beck; Hans Salwender; Martina Emde; Uta Bertsch; Christina Kunz; Christoph Scheid; Mathias Hänel; Katja Weisel; Thomas Hielscher; Marc S Raab; Hartmut Goldschmidt; Anna Jauch; Jérôme Moreaux; Anja Seckinger
Journal:  J Hematol Oncol       Date:  2019-06-26       Impact factor: 17.388

5.  The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.

Authors:  Leo Rasche; Carolina Schinke; Francesco Maura; Michael A Bauer; Cody Ashby; Shayu Deshpande; Alexandra M Poos; Maurizio Zangari; Sharmilan Thanendrarajan; Faith E Davies; Brian A Walker; Bart Barlogie; Ola Landgren; Gareth J Morgan; Frits van Rhee; Niels Weinhold
Journal:  Nat Commun       Date:  2022-08-03       Impact factor: 17.694
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.